CareLit · DOI-Nachweis · Pneumologie
First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial
DOI 10.1055/s-0039-3403360
Bibliografische Angaben
Nachweis in CareLit
Autor:innenMJ Hochmair, DR Camidge, HR Kim, MJ Ahn, JCH Yang, J Youn Han, KH Lee, A Delmonte, MR Garcia Campelo, DW Kim, F Griesinger, E Felip, R Califano, A Spira, S Gettinger, M Tiseo, Q Ni, P Zhang, S Popat
ZeitschriftPneumologie
AusgabeS 01 S 01/2020
Jahrgang / SeitenJg. 74
Kernaussage aus der Literatur
Abstract-Vorschau
First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial
Zitieren
Zitierempfehlung
MJ Hochmair, DR Camidge, HR Kim, MJ Ahn, JCH Yang, J Youn Han, KH Lee, A Delmonte, MR Garcia Campelo, DW Kim, F Griesinger, E Felip, R Califano, A Spira, S Gettinger, M Tiseo, Q Ni, P Zhang, S Popat (2020) First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial. Pneumologie, 74 (S 01 S 01). https://doi.org/10.1055/s-0039-3403360
Mit CareLit weiterarbeiten